Indian drug developer Hetero said on Monday it has received emergency use approval from the country's health authorities to make a generic version of Roche Holding AG's COVID-19 drug.
Hetero expects to make the treatment, tocilizumab, available in India by the end of the month under the brand name Tocira. Tocilizumab has been facing a global shortage as the highly contagious COVID-19 Delta variant drives up cases in several countries.
COVID-19 cases in India have declined from levels hit during the second wave in April and May, although health experts believe that the country should brace for a third wave by October.
Roche's blockbuster arthritis drug, tocilizumab, cuts the risk of death among patients hospitalised with severe COVID-19 along with shortening the recovery time and reducing the need for mechanical ventilation.
Tocira will be made by Hetero's unit at its Hyderabad facility.
Hetero, which makes COVID-19 treatments like remdesivir and favipiravir, had also sought emergency approval for Merck's COVID-19 drug molnupiravir in July.
(This story has not been edited by NDTV staff and is auto-generated from a syndicated feed.)
Covid-19 Cases Rising Again: WHO Issues Urgent Alert On Potentially Severe Variants Covid-19 Still Driving High Mortality Rate In This Country Biden Returns To White House After Exiting US Presidential Race Parents Gave Names Of Interns, Doctors To CBI In Kolkata Horror: Sources How Extreme Weather Is Leading To Rise In Child Marriages In Pakistan 3 Days After Big Order On Deposits With SBI And PNB, Karnataka Hits Pause "Far From Over" But Joe Biden Has High Hopes For Gaza Ceasefire Indian Student In UK Develops Revolutionary Carbon-Extracting Biomaterial Video: Woman Tries To Jump Off Mumbai's Atal Setu, Saved By Driver, Cops Track Latest News Live on NDTV.com and get news updates from India and around the world.